Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies.

[1]  F Levi,et al.  European cancer mortality predictions for the year 2014. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  I. Reis,et al.  A Phase II Trial of nab-Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer , 2013, American journal of clinical oncology.

[3]  M. Hidalgo,et al.  Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). , 2013 .

[4]  V. Heinemann,et al.  Systemic treatment of advanced pancreatic cancer. , 2012, Cancer treatment reviews.

[5]  Edward J. Kim,et al.  Abstract A40: Cancer stem cells (CSC) and inhibition of hedgehog (Hh) pathway signaling in advanced pancreatic cancer: GDC-0449 in combination with gemcitabine (Gem). , 2012 .

[6]  M. Di Marco,et al.  Hedgehog signaling: from the cuirass to the heart of pancreatic cancer. , 2012, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[7]  M. Hidalgo,et al.  Antitumor activity of nab-paclitaxel and gemcitabine in resectable pancreatic cancer. , 2012 .

[8]  M. Borad,et al.  Targeting hyaluronan (HA) in tumor stroma: A phase I study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of pegylated hyaluronidase (PEGPH20) in patients with solid tumors. , 2012 .

[9]  F Levi,et al.  European cancer mortality predictions for the year 2012. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  S. Temple,et al.  Molecular Characterisation of Transport Mechanisms at the Developing Mouse Blood–CSF Interface: A Transcriptome Approach , 2012, PloS one.

[11]  Carlos Cuevas,et al.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[12]  Ahmedin Jemal,et al.  Cancers with increasing incidence trends in the United States: 1999 through 2008 , 2012, CA: a cancer journal for clinicians.

[13]  D. Tuveson,et al.  nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. , 2012, Cancer discovery.

[14]  H. Friess,et al.  The impact of the activated stroma on pancreatic ductal adenocarcinoma biology and therapy resistance. , 2012, Current molecular medicine.

[15]  C. Fuchs,et al.  A phase Ib trial of IPI-926, a hedgehog pathway inhibitor, plus gemcitabine in patients with metastatic pancreatic cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  K. Behrns.  FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer , 2012 .

[17]  A. Tsao.  Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial , 2012 .

[18]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[19]  S. Kakolyris,et al.  Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study , 2012, Cancer Chemotherapy and Pharmacology.

[20]  A. Maitra,et al.  Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Temple,et al.  SPARC/osteonectin, an endogenous mechanism for targeting albumin to the blood–cerebrospinal fluid interface during brain development , 2011, European Journal of Neuroscience.

[22]  A. Ko.  FOLFIRINOX: a small step or a great leap forward? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Qiwei Yang,et al.  Secreted Protein Acidic and Rich in Cysteine Is a Matrix Scavenger Chaperone , 2011, PloS one.

[24]  L. Diaz,et al.  A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma , 2011, Cancer Chemotherapy and Pharmacology.

[25]  M. Zavoral,et al.  Molecular biology of pancreatic cancer. , 2011, World journal of gastroenterology.

[26]  M. Borad,et al.  Phase I trial erlotinib, gemcitabine, and the hedgehog inhibitor, GDC-0449. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. El-Khoueiry,et al.  A phase I study of two different schedules of nab-paclitaxel (nab-P) with ascending doses of vandetanib (V) with expansion in patients (Pts) with pancreatic cancer (PC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Bachet,et al.  Treatment of Pancreatic Cancer: What Can We Really Predict Today? , 2011, Cancers.

[29]  M. Willson,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011 .

[30]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[31]  M. Reni,et al.  A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen) , 2011, Cancer Chemotherapy and Pharmacology.

[32]  D. Mavroudis,et al.  Second-line chemotherapy with Capecitabine (Xeloda) and Docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial , 2011, Cancer Chemotherapy and Pharmacology.

[33]  J. Kleeff,et al.  Tumor microenvironment and progression of pancreatic cancer. , 2010, Experimental oncology.

[34]  Muhammad Wasif Saif,et al.  Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study. , 2010, Anticancer research.

[35]  G. Hostetter,et al.  Radiosensitization and Stromal Imaging Response Correlates for the HIF-1 Inhibitor PX-478 Given with or without Chemotherapy in Pancreatic Cancer , 2010, Molecular Cancer Therapeutics.

[36]  S. Anant,et al.  Cancer stem cells: a novel paradigm for cancer prevention and treatment. , 2010, Mini reviews in medicinal chemistry.

[37]  M. Falconi,et al.  Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  Tibor Schuster,et al.  Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages , 2010, PLoS medicine.

[39]  Julien Reyal.  Arterial flow focalization could increase tissue oxygen partial pressure, or trigger endothelial shear stress - a new concept to overcome cancer hypoxia-induced radiotherapy resistance, or stimulate liver regeneration during fulminant hepatitis. , 2010, Medical hypotheses.

[40]  L. Jian-hua,et al.  Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine plus Capecitabine in Patients with Advanced Pancreatic Cancer , 2010 .

[41]  R. Goldberg,et al.  Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  A. Maitra,et al.  The hedgehog pathway and pancreatic cancer. , 2009, The New England journal of medicine.

[43]  Rolf A. Brekken,et al.  SPARC: a matricellular regulator of tumorigenesis , 2009, Journal of Cell Communication and Signaling.

[44]  A. Bradshaw.  The role of SPARC in extracellular matrix assembly , 2009, Journal of Cell Communication and Signaling.

[45]  M. Reni,et al.  Carbohydrate antigen 19‐9 change during chemotherapy for advanced pancreatic adenocarcinoma , 2009, Cancer.

[46]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[47]  Helmut Friess,et al.  Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. , 2009, Neoplasia.

[48]  G. Feldmann,et al.  A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development , 2009, Molecular Cancer Therapeutics.

[49]  N. Desai,et al.  Nab Technology : A Drug Delivery Platform Utilising Endothelial gp 60 Receptor-based Transport and Tumour-derived SPARC for Targeting I , 2009 .

[50]  F. Rödel,et al.  Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma , 2008, Cancer biology & therapy.

[51]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[52]  M. Mullendore,et al.  Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer , 2008, Gut.

[53]  C. Heeschen,et al.  Metastatic cancer stem cells: A new target for anti-cancer therapy? , 2008, Cell cycle.

[54]  R. Labianca,et al.  Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer , 2008, BMC Cancer.

[55]  D. Tuveson,et al.  Dynamics of the immune reaction to pancreatic cancer from inception to invasion. , 2007, Cancer research.

[56]  C. Heeschen,et al.  Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. , 2007, Cell stem cell.

[57]  Helmut Friess,et al.  Pancreatic cancer microenvironment , 2007, International journal of cancer.

[58]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  D. V. Von Hoff,et al.  Tumor-stroma interactions in pancreatic ductal adenocarcinoma , 2007, Molecular Cancer Therapeutics.

[60]  C. Iacobuzio-Donahue,et al.  Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  M. Omary,et al.  The pancreatic stellate cell: a star on the rise in pancreatic diseases. , 2007, The Journal of clinical investigation.

[62]  P. Dalerba,et al.  Identification of pancreatic cancer stem cells. , 2006, Cancer research.

[63]  M. Desai,et al.  The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis , 2007, Cancer Chemotherapy and Pharmacology.

[64]  H. Einsele,et al.  Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  A. Jimeno,et al.  Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer , 2006, Molecular Cancer Therapeutics.

[66]  Kenji Yokoi,et al.  Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. , 2005, Cancer research.

[67]  Michael Hawkins,et al.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  J. Furuse,et al.  Primary tumor of pancreatic cancer as a measurable target lesion in chemotherapy trials. , 2005, Japanese journal of clinical oncology.

[69]  H. Friess,et al.  Osteonectin Influences Growth and Invasion of Pancreatic Cancer Cells , 2005, Annals of surgery.

[70]  Ireland,et al.  Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas. , 2005 .

[71]  M. Reni,et al.  Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. , 2005, The Lancet. Oncology.

[72]  R. Labianca,et al.  Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  S Pancreatic,et al.  Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas , 2005, Gut.

[74]  P. Soon-Shiong,et al.  SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs taxol , 2005 .

[75]  Robert Jaster,et al.  Molecular regulation of pancreatic stellate cell function , 2004, Molecular Cancer.

[76]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[77]  R. Brekken,et al.  SPARC regulates TGF‐beta1‐dependent signaling in primary glomerular mesangial cells , 2004, Journal of cellular biochemistry.

[78]  C. Bucana,et al.  Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[79]  T. Fujita,et al.  SPARC stimulates the synthesis of OPG/OCIF, MMP-2 and DNA in human periodontal ligament cells. , 2002, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[80]  R. Ross,et al.  Inhibition of PDGF‐stimulated and matrix‐mediated proliferation of human vascular smooth muscle cells by SPARC is independent of changes in cell shape or cyclin‐dependent kinase inhibitors , 2002, Journal of cellular biochemistry.

[81]  M. Ducreux,et al.  A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. , 2000, European journal of cancer.

[82]  E. Sage,et al.  Primary mesenchymal cells isolated from SPARC-null mice exhibit altered morphology and rates of proliferation. , 1999, Molecular biology of the cell.

[83]  E. Sage,et al.  SPARC (BM-40, Osteonectin) Inhibits the Mitogenic Effect of Vascular Endothelial Growth Factor on Microvascular Endothelial Cells* , 1998, The Journal of Biological Chemistry.

[84]  R. Timpl,et al.  Crystal structure and mapping by site‐directed mutagenesis of the collagen‐binding epitope of an activated form of BM‐40/SPARC/osteonectin , 1998, The EMBO journal.

[85]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  E. Sage,et al.  SPARC antagonizes the effect of basic fibroblast growth factor on the igration of bovine aortic endothelial cells , 1992, Journal of cellular biochemistry.

[87]  E. A. Everitt,et al.  SPARC, a secreted protein associated with cellular proliferation, inhibits cell spreading in vitro and exhibits Ca+2-dependent binding to the extracellular matrix , 1989, The Journal of cell biology.

[88]  P. Bornstein,et al.  Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. , 1984, The Journal of biological chemistry.